|
Generic Name for RITUXAN
Rituximab 10mg/mL; soln for IV infusion; preservative-free.
Legal Classification:
Rx
Pharmacological Class for RITUXAN
B-lymphocyte-restricted differentiation antigen [CD20] inhibitor.
Manufacturer of RITUXAN
Genentech, Inc.
|
Indications for RITUXAN
For the treatment of Wegener's granulomatosis and microscopic polyangiitis, in combination with glucocorticoids.
Other Indications for RITUXAN
Adult dose for RITUXAN
Give by IV infusion. Premedicate with an antihistamine and acetaminophen prior to each infusion. First infusion: initially at a rate of 50mg/hr; may increase infusion rate in 50mg/hr increments every 30 minutes. Subsequent infusions: initially at a rate of 100mg/hr; may increase infusion rate in 100mg/hr increments every 30 minutes. Both: max 400mg/hr if infusion reactions do not occur. 375mg/m2 once weekly for 4 weeks. Begin glucocorticoids within 14 days prior to or with initiation of Rituxan and continue during and after the 4 week course (see literature). Retreatment: safety and efficacy not established.
Children's dosing for RITUXAN
Not recommended.
Warnings/Precautions for RITUXAN
Severe, active infections: not recommended. Discontinue if severe infusion or mucocutaneous reactions occur (eg, hypoxia, pulmonary infiltrates, acute respiratory distress syndrome, MI, ventricular fibrillation, cardiogenic shock, Stevens-Johnson syndrome, toxic epidermal necrolysis). Tumor lysis syndrome (esp. with high tumor burden); monitor for renal toxicity, fluid balance, electrolyte abnormalities (correct if occurs). Monitor for new-onset neurologic manifestations; discontinue if progressive multifocal leukoencephalopathy (PML) develops. Pre-existing cardiovascular disease; monitor during and after treatment. Hepatitis B reactivation with fulminant hepatitis may occur; monitor for signs of active HBV infection, discontinue if occurs. Monitor CBCs, platelet counts at 2-4 month intervals during treatment, then periodically. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
Interactions for RITUXAN
Live virus vaccines: not recommended. Renal toxicity with cisplatin. Concomitant immunosuppressants other than corticosteroids have not been studied.
Adverse Reactions for RITUXAN
Infections, GI upset, headache, muscle spasms, anemia, peripheral edema; myelosuppression (eg, lymphopenia, neutropenia, leukopenia, anemia, thrombocytopenia), infusion reactions (may be fatal), mucocutaneous reactions (may be fatal), progressive multifocal leukoencephalopathy, viral infections (discontinue if serious), tumor lysis syndrome, renal toxicity, bowel obstruction/perforation, hepatitis B reactivation with fulminant hepatitis, cardiac arrhythmias (discontinue if serious).
How is RITUXAN supplied?
Single-use vial (10mL, 50mL)—1